



July 28, 2025

FOR IMMEDIATE RELEASE

Company name	Resorttrust, Inc.
Representative	Ariyoshi Fushimi, President and COO
Code	4681, Prime of Tokyo Stock Exchange and Premier of Nagoya Stock Exchanges

**CICS, Inc. (a consolidated subsidiary of Resorttrust, Inc.) has achieved the primary endpoint in a domestic phase II clinical trial of BNCT (Boron Neutron Capture Therapy) for the treatment of angiosarcoma**

Resorttrust, Inc. hereby announces that Cancer Intelligence Care Systems, Inc., its consolidated subsidiary (“CICS,” President: Tetsuya Furukawa; Head Office: Koto-ku, Tokyo), and STELLA PHARMA CORPORATION (“STELLA PHARMA,” President & COO: Koki Uehara; Head Office: Chuo-ku, Osaka), have achieved the primary endpoint in a domestic phase II clinical trial of BNCT (Boron Neutron Capture Therapy) for the treatment of angiosarcoma<sup>\*1</sup>.

This study was conducted at the National Cancer Center Hospital with the primary objective of evaluating the efficacy of BNCT using CICS's accelerator-based neutron capture therapy device (CICS-1) and STELLA PHARMA's boron drug (SPM-011). The subjects were patients of unresectable angiosarcoma with locally advanced or locally recurrent disease for whom chemoradiotherapy or radiotherapy was not feasible and who had no other effective treatment options. In this study, the primary endpoint was defined as the objective response rate<sup>\*2</sup>, and was conducted as a single-arm trial<sup>\*3</sup>.

CICS is aiming to commercialize its accelerator-based neutron capture therapy device in 2026 and is considering submitting a marketing authorization application based on the results of this study. The detailed results of this study are scheduled to be presented at the ESMO Congress 2025 (European Society for Medical Oncology), which will be held in Berlin, Germany this October. The impact of this matter on the Company's consolidated financial results for the current fiscal year is expected to be minimal.

The Resorttrust Group entered the medical business in 1994 and began operating a membership-based comprehensive medical club. At the Yamanakako Clinic, Positron Emission Tomography (hereinafter “PET”), which was then a research-use device, was introduced for cancer screening, making a significant contribution to the widespread use of PET in Japan. Today, in addition to screening services, the Group is expanding its solutions in the field of treatment and also supports the operation of facilities providing advanced cancer immunotherapy.

Under its brand identity “Together for a Wonderful Life”, the Resorttrust Group promotes the slogan “Contributing to healthy longevity and personal wellbeing in the age of 100 years of life.” Driven by the desire to create a society where no one loses a loved one to cancer, the Group has been involved in cancer screening and treatment. Through its commitment to BNCT, the Group aims to help create a more affluent, happy time and to bring new hope to cancer treatment both in Japan and across Asia.

\*1 Angiosarcoma

Angiosarcoma is a type of cancer that originates from the endothelial cells of blood vessels. It can occur throughout the body, most commonly in the skin. It is considered to be very rare and highly malignant, and no effective standard treatment has been established.

\*2 Objective response rate

A clinical indicator used to assess the effectiveness of a treatment. It represents the proportion of patients in a clinical trial who experienced either a partial response (a reduction in tumor size of 30% or more from baseline) or a complete response (disappearance of the tumor with no detectable evidence on imaging or examination).

\*3 Single-arm trial

A trial in which all participants receive the same treatment.


### About BNCT

Boron neutron capture therapy (BNCT), a form of radiotherapy, is a new method of treating cancer. When patients receive a boron agent, a boron compound ( $^{10}\text{B}$ ) accumulates in their cancer cells. The area of the tumor is then exposed to an external source of extremely low-energy neutron radiation, which while having little effect on the human body, causes the boron ( $^{10}\text{B}$ ) to capture neutrons, resulting in a reaction that causes the release of alpha rays and  $^7\text{Li}$  nuclei. BNCT is therefore a medical treatment that leverages radiation to selectively kill cancer cells. In addition, in principle, as treatment is completed with a single neutron irradiation, expectations are for this to be a treatment that causes little damage to the body.

### About CICS-1

CICS is an accelerator-based neutron capture therapy device jointly developed by CICS and the National Cancer Center Hospital. It generates neutrons by accelerating protons using an RFQ (radio-frequency quadrupole) linear accelerator and colliding them with a lithium target. A key feature of this system is the minimal inclusion of fast neutrons, which can have significant harmful effects on the human body. In addition, because the energy of the generated neutrons is 800 keV or lower, the system allows for downsizing of the moderation setup needed to slow the neutrons down to around 10 keV, the energy level suitable for BNCT.

Unlike existing devices that irradiate neutrons horizontally to patients, the device developed by CICS can irradiate vertically, making it potentially applicable to conditions that were previously difficult to treat.



Accelerator-based neutron capture therapy device CICS-1



BNCT irradiation room at the National Cancer Center Hospital